Interim analysis of hard-to-cure1 patients administered MK-5172/MK-8742 with and without ribavirin for 12 or 18 weeks showed sustained viral response2 , 4 to 8 weeks after the completion of therapy : "These findings provide additional clinical evidence regarding the potential of MK-5172/MK-8742 in treating a broad spectrum of HCV patients."
http://ift.tt/1kyLtbM
http://ift.tt/1kyLtbM
No comments:
Post a Comment